Roche India launched PHESGO, therapy for breast cancer

The first ever fixed dose formulation in oncology to combine two monoclonal antibodies – Perjeta (pertuzumab) and Herceptin

Roche Pharma announced the India launch of PHESGO – the first ever fixed dose formulation in oncology to combine two monoclonal antibodies – Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC injection.

PHESGO was first approved by the in June 2020 during the peak of the Covid pandemic, by the European Medicines Agency (EMA) in December 2020, and has been recognised in the NCCN treatment guidelines. In India, PHESGO was approved by the DCGI in October 2021 and the import license was granted in January 2022. Globally, over 17000 breast cancer patients have benefitted from PHESGO as on December 2021. 

Commenting on the launch, V Simpson Emmanuel, CEO and MD, Roche Pharma India said, “PHESGO is a path breaking drug that will provide convenience and improve quality of life of patients suffering from breast cancer by significantly reducing the in-clinic time for them. Patients and their caregivers can now look forward to spending less time at the hospital and more time doing what they like most. It will also enhance the efficiency of healthcare systems since it requires less preparation and administration time. Faster administration frees up time for both patients and healthcare professionals and provides cost saving benefits to healthcare systems. PHESGO is one more example of Roche’s commitment to our purpose of ‘Doing now what patients need next’ and pioneering efforts in the breast cancer treatment space.”

PHESGO, the Dual Innovator FDC provides the best Standard of Care for HER2+ Breast cancer patients, offering time tested efficacy at 20 per cent lesser cost. With IRDAI widening insurance coverage to include various modern treatment methods, immunotherapy – monoclonal antibodies given as an injection are now covered by all insurers. This, along with support through Roche’s Patient Assistance Programme will help significantly drive access to standard of care treatment for breast cancer patients in India. Also, during the Covid pandemic, cancer patients were significantly impacted due to delayed treatment interventions. PHESGO can help breast cancer patients continue receiving their treatment due to significantly shorter administration times and convenience of subcutaneous administration, potentially moving the treatment from oncology wards to daycare and OPD settings. 

“Cancer treatment is very resource intensive and time consuming. Patients have to visit the hospital many times and undergo long infusion procedures. This puts a huge demand on the patient, their caregivers, and the healthcare staff at a hospital. PHESGO can significantly improve the quality of life of a patient and their caregiver while undergoing treatment and reduce the burden on the healthcare professionals, enabling them to treat more patients,” says Dr Shona Nag, Director of Oncology, Sahyadri Group of Hospitals, Pune.


Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Back to top button